FDA expands access to gemcitabine for pancreatic cancer.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015507:Drugs, Investigational; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D015507:Drugs, Investigational; D003841:Deoxycytidine; D000093542:Gemcitabine